chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Developed shingles outbreak to left chest approximately 60 hours after 2nd Covid vaccine; This is a spontaneous report from a contactable nurse. A 56-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via intramuscular route of administration in the left arm on 07Apr2021 at 12:00 (at the age of 56-year-old), as a single dose for COVID-19 immunisation. Medical history included attention deficit hyperactivity disorder (ADD), hashimoto's disease, iritis. The patient was allergic to iodine. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included fluoxetine hydrochloride (PROZAC) and amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL) from an unknown date for an unspecified indication, unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 17Mar2021 at 14:30 (at the age of 56-year-old), as a single dose for COVID-19 immunisation. On 10Apr2021 at 06:00, approximately 60 hours after 2nd Covid vaccine, the patient developed shingles outbreak to left chest. The adverse event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the event which included treatment with acyclovir. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event developed shingles outbreak to left chest approximately 60 hours after 2nd Covid vaccine was not resolved at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
p/receiving Typhoid vax, pt devel sweating & flu-like sx including muscle aches; Also, devel 2-3 in area of erythema & induration @ inject site; 3 wks later, induration persisted while all other sx abated;
Patient received the 1st Covid 19 Pfizer vaccine on 1/27/21 and and the 2nd Covid 19 Pfizer Vaccine on 2/17/21.  Patient presents on 5/4/21  with a history of  not feeling herself for a few days.  Also a report of increased bruising.  Labs were drawn on 5/4 and patient has low platelets of 33.  Labs were repeated on 5/5 and platelets were even lower at 25.  Referred to hematology and oncology.
Their wasn't an adverse reaction. It could be an adverse reaction if I don't know if I can replace the first vaccine. Because I really want to go somewhere else to receive another vaccine. PLEASE HELP AND TELL ME WHAT I CAN DO. THANK YOU.
Tingling in right arm and back of neck, some chest pain over the course of a few days - eventually did a telehealth visit on Monday, Sept 6 and they recommended an EKG to rule out any heart problems.  Visited ER at the hospital that evening for EKG, bloodwork, and chest x-ray.  All came back normal.  Followed up with cardiologist and did stress test as a precaution.  Some symptoms continue (primarily numbness in right arm) and mild occasional chest pain, but these are likely stress induced.  Everything appears to be good with my heart.  No suspicion that the vaccine is related in any way.
Dry mouth; Dry tongue; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 52-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 14Nov2022 as dose 5 (booster), single (Lot number: GJ3275) at the age of 52 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (DOSE 2; MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (DOSE 3 (BOOSTER); MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (DOSE 4 (BOOSTER); MANUFACTURER UNKNOWN), for COVID-19 Immunization. The following information was reported: DRY MOUTH (non-serious) with onset 15Nov2022, outcome "unknown"; TONGUE DRY (non-serious) with onset 15Nov2022, outcome "unknown", described as "Dry tongue". Therapeutic measures were not taken as a result of dry mouth, tongue dry.  Additional information: It was also reported that the patient did receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient did not receive any medications within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient had been tested for COVID-19.   No follow-up attempts are possible. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201333363 Same patient, different drug/ AE;
SWELLING, HARD LUMP ON SITE OF INJECTION AND EXTREME PAIN, 100F FEVER. COULDN'T LIFT ARM UP SIDEWAYS FOR ALMOST 1 WEEK. NEVER HAPPENED PREVIOUSLY W/ TETANUS SHOT. TOOK IBUPROFEN FOR PAIN/FEVER FOR ALMOST 1 WEEK.
Skin rash starting with intense itch, swelling, redness, vesicles turning into scaling, still ongoing after 4 weeks.
Redness, warmth, pronounced hard painful mass at site one day after and lasting for about 8 days.  Generalized myalgia daily on arising in the morning lasting for a few hours in the morning. Occasional headaches with shoulder soreness.
Headache, Myalgia, Arthralgia, Chills, fatigue, sinus congestion Narrative:
Patient has red rash at site of injection. Patient advised to apply BENADRYL to the area. If rash persists see the doctor.
This spontaneous report as received from healthcare professional refers to an unspecified patients of unknown age and unknown gender. The unspecified patients pertinent medical history was not reported. Since 10-MAR-2015, the unspecified number of patients were administered unspecified doses of improperly stored GARDASIL (lot # K006191 and expiry date: 02-FEB-2017). No adverse effects were reported. No product quality complaint (PQC) was reported GARDASIL. This is one of the several reports from the same reporter.  Additional information has been requested.
Vaccine administered after more than 1 temperature excursion; Vaccine administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Feb-2021 at 4:15 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 08-Feb-2021 at 4:15 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 60.02  Concomitant products were not provided.  On 08-Feb-2021, Excursion time was 10 AM and 11 AM, temperature was 29 and 35, total doses given for the day was 30, condition of vaccine prior to administration was not frozen, vaccine was moved to fridge on 02-Feb-2021, vial was moved to clinic on 08-Feb-2021. 3 vials were sent to clinic. Vaccine BUD date was 04-Mar-2021.    The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a traceable temperature monitor at every hour. After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature. It was reported that the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021. The HCP explained that each time a vial was put into a cooler, there was a period of time of 1 hour or 1 hour and a half approximately, when the temperature data logger registered 34 or 35 degree F.  Treatment medications were not reported.
Yesterday I finished the vaccination and now I have measles on my skin and itching. Is it an allergic reaction? Is this serious?
This is a spontaneous report from a non-contactable pharmacist. A male patient of an unspecified age and race/ethnicity received the first single dose of PREVNAR 13 via an unspecified route of administration, in December (unspecified date), for immunisation. Medical history included stem cell transplant. The patient's concomitant medications were not reported. The patient had a swelling and a hard nodule in the center right after injection on an unspecified date. Events outcome was unknown. No follow-up attempts possible. No further information expected.
Patient received Kinrix (DTaP,IPV, MMR & Varicella 04/07/09. He was seen in the office this date due to pain, itching and swelling in left arm for 2 days. He was prescribed Ibuprofen 11/2 tsp every 6 hours for 2 days and was given Benadryl 12.5 mg in the office
around 5 to 10 minutes after her vaccination, patient reported feeling dizzy/lightheaded, "seeing stars" and  reported that the symptoms "comes and goes".  Patient reported eating lunch that day.  Paramedics were called and came to examine patient
Sore arm for first 2 weeks.  Strong headaches first 2 days, continued daily morning headache 15 days.  Stomach cramps and diarrhea on and off, but pronounced on day 10 along with low grade fever (99.5) and fatigue.  Day 15 headache increased in severity, fatigue.  Joint pain, particularly elbows and knees.
Felt fine for a few days (minus deltoid soreness).  Then developed a stuffy, pressure- filled head, knife-like pains in certain parts of back of head.  This progressed to focused pains in hip joint, pancreas/kidney? thoracic back.  Just prior to this vaccination I obtained a AB level of 14.9 ( my severe cytokine storm non-inpatient infection was 4 months prior - for which I visited ER 3 times and also had OP monoclonal AB infusion).  I had a scope scheduled  ENT who told me that my I was very inflamed and started me on ABT.  She believed it could be related to post-COVID. I believe the vaccine stirred up a possible response to maybe some retained AG.  I will not get the second dose unless someone can convince me that it will be safe.
24 hours waves of nausea and sweats started, then a short time later a bad headache and about 40 minutes later diarrhea and chills. Also very fatigued and just feeling off.
Vaccine administered beyond Expiration date. However, per Moderna- all vaccines met viability requirements.  Completing VAERS per Regulatory Authority requirements.
Information has been received from a lawyer regarding a case in litigation concerning a female patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. In 2007, the patient was inoculated with ZOSTAVAX, (lot# and route unknown) as recommended for routine adult health maintenance and for the prevention of shingles. The vaccine did not prevent shingles as intended and the patient subsequently contracted a persistent strain of herpes zoster. During 2015, the patient was treated by a physician for a persistent and severe vesicular rash, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
Patient experienced cellulitis-like reaction on the injection site. Patient's arm was red, swollen, hot and painful. The symptoms became apparent on the same day the vaccine was administered. Patient also experienced fever the arm was red from shoulder top up to elbow.
Lethargy; severe left arm pain; chills; diarrhea; severe violent vomiting on empty stomach (black bile) for 2-4 hours; unable to keep food down for another 12 hours;; severe violent vomiting on empty stomach (black bile) for 2-4 hours; unable to keep food down for another 12 hours;; severe body aches and chills; diarrhea 48 hours after; tiredness; This is a spontaneous report from a contactable (patient). A 32-years-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: EW 0175), dose 2 via an unspecified route of administration, administered in Arm Left on 27Apr2021 at 14:15 (at the age of 32-years-old) as dose 2, single for covid-19 immunisation. Medical history included , covid-19, breathing issues, fatigue, brain fog, "COVID long hauler" - extended  effects including brain fog, fatigue and breathing issues. Historical Vaccine included BNT162B2 (Lot/batch Number: EW0150) administered on 06Apr2021 at 14:15 in Left arm as dose 1 for covid-19 immunisation (at the age of 32-years-old). The patient's concomitant medications were not reported.  On 29Apr2021 at 05:00, the patient experienced lethargy, severe left arm pain, tiredness, chills, diarrhea, severe violent vomiting on empty stomach (black bile) for 2-4 hours; unable to keep food down for another 12 hours, severe body aches and chills; diarrhea 48 hours after. It was reported the patient had 0-24 hours after injection general lethargy and 39 hours after vaccination severe violent vomiting. The patient received no other vaccine in four weeks. No treatment was given for the events. Patient was covid prior vaccination and did not test for covid post vaccination. Outcome of the events were recovering.   No follow-up attempts are possible. No further information is expected.
Patient experienced tingling from her shoulder down to her finger tips. no treatment was given. patient recovered from tingling sensation
got hospitalized due to sepsis after the first dose.; This is a spontaneous report from a Pfizer-sponsored program, patient's daughter. A female patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot number was not reported), via an unspecified route of administration on 10Feb2021 as a single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The reporter asked to make a schedule change since her mother got hospitalized due to sepsis after the first dose. The first dose was on 10Feb2021, next dose is on 04Mar2021. The outcome of the event was unknown.  Information about lot/batch number has been requested.
felt especially fatigued the last 4 days. I tested positive on 30Jul; felt especially fatigued the last 4 days. I tested positive on 30Jul; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 27-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 17Mar2021 as dose 1, single (Lot number: EN6208), in left arm, on 07Apr2021 as dose 2, single (Lot number: ER8734), in left arm and on 27Aug2021 as dose 3 (booster), single (Lot number: FC3180) at the age of 26 years, in left arm for COVID-19 immunization; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 03Feb2022 as dose 4 (booster), single (Lot number: 022J21A), in left arm for COVID-19 immunization. The patient's relevant medical history included: "Selective IgA deficiency" (unspecified if ongoing); "IgG subclass deficiency" (unspecified if ongoing). There were no concomitant medications. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 30Jul2022, outcome "not recovered" and all described as "felt especially fatigued the last 4 days. I tested positive on 30Jul". The patient underwent the following laboratory tests and procedures: Covid test: (unspecified date) Positive, notes: I took a COVID test and it was positive; (30Jul2022) Positive, notes: I have felt especially fatigued the last 4 days. I tested positive on 30Jul; (09Aug2022) Positive, notes: then I just retested positive today 09Aug; PCR test (06Aug2022) Negative, notes: after testing negative on a PCR on 06Aug; rapid test (04Aug2022) Negative, notes: my rapid tests were negative starting 04Aug; (08Aug2022) Negative, notes: and on a rapid test on 08Aug. Therapeutic measures were taken as a result of vaccination failure, covid-19.  Additional information:: The patient woke up this morning feeling a bit of a sore throat and her nose was pretty stuffy. She took her allergy medicine and the stuffiness went away, but she was still feeling pretty low energy so she took a Covid test and it was positive. She have felt especially fatigued the last 4 days. She tested positive on 30Jul, my rapid tests were negative starting 4Aug, and then she just retested positive today (09Aug) after testing negative on a PCR on 06Aug and on a rapid test on 08Aug.
My menstrual periods have been much worse since receiving the vaccines. Very heavy flow lasting about 10 days. Severe cramping lasting 3-4 days.
Headache (shorty after shot was given), soreness in left arm, tiredness, chills, muscle cramps and spasms, dizziness and fever (day 3 still have nagging headache)
Not feeling well; chills; muscle aches; headache; ears bothering; stuffy/runny nose; stuffy/runny nose; This is a spontaneous report from a non-contactable nurse (patient). A 43-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot number: EL0140), intramuscularly in the right arm, on 18Dec2020 at 06:00 (at the age of 43-years-old) at a single dose for COVID-19 immunization. Medical history included hypothyroid, breast cancer, and penicillin allergy. The patient was not pregnant at the time of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications, taken within two weeks of vaccination, included levothyroxine (MANUFACTURER UNKNOWN) and tamoxifen (MANUFACTURER UNKNOWN). Other concomitant medications included unspecified multivitamin. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced not feeling well, chills, muscle aches, headache, ears bothering, and stuffy/runny nose on 25Dec2020 at 20:00. The events were reported as non-serious. No therapeutic measures were taken as a result of the events. The clinical outcome of not feeling well, chills, muscle aches, headache, ears bothering, and stuffy/runny nose was unknown. It was also reported that since the vaccination, the patient had not been tested for COVID-19.   No follow-up attempts are possible. No further information is expected.
Lightheadedness; This is a spontaneous report received from a non-contactable other healthcare professional. A 36-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot no: EN6205), via an unspecified route of administration as 1st dose, single dose on 16Mar2021 (at the age of 36-years-old) for COVID-19 immunization. Medical history included ongoing asthma on Symbicort and Albuterol, ongoing seasonal allergy, affective disorder from an unknown date. Concomitant medications included cetirizine hydrochloride (Zyrtec) taken for seasonal allergy from an unknown date; bupropion hydrochloride (Wellbutrin) taken for affective disorder from an unknown date; albuterol salbutamol (Albuterol) taken for asthma (from an unknown date; budesonide, formoterol fumarate (Symbicort) taken for asthma, from an unknown date. On 16Mar2021, during her 15 minutes waiting period after the injection, the patient began to experience lightheadedness. She denied rash, hives, welts, difficulty breathing, difficulty swallowing, wheezing, throat tightness, hoarseness, stridor, itching, dizziness, facial swelling, lip swelling and tongue swelling PMH includes asthma (on Symbicort and albuterol). Takes Zyrtec daily for seasonal allergies and on Wellbutrin for mood stabilizing. She did not eat or drink anything today other than coffee. She has not taken her zyrtec or albuterol dose today. The seriousness criteria of the event was reported as non-serious by the reporter. Treatment included: water and snacks. Follow up response to treatment was excellent. The patient was discharged and stable to go home and follow up with PCP. The clinical outcome of the event light-headedness was resolved on an unspecified date.  No follow-up attempts were possible. No further information was expected.
mom states lt hosp 5PM pt had cried very hard p/inj;pt fell asleep during drive home;pt awakened crying & cried from 6PM through 11PM unless held;
14 days after receiving 1st dose vaccine, 3 inches by 4 inches hive like rash. Left arm sore, in the area, down the arm, thru the elbow and effecting the wrist. Hot to the touch and very sore at the rash site. This started on around 4/9/2021 approximately 10 days post vaccine.
My son has a lump (marble, size of pea) in his right leg after vaccination. It's been over a month and it hasn't gone away. We had him x rayed (15 days later). The Dr wanted to be sure no needle broke off/or foreign object was in him but x ray came out ok.
J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 7/11/2022 SEPSIS UNSPECIFIED ORGANISM
Covid arm. Very red,  extremely itchy and hot to the touch. Appeared at injection site 6 days after first vaccine and started to subside after 3 days.
Lyme Disease; This is a spontaneous report from a Pfizer-sponsored program. A contactable nurse reported that a male patient of unspecified age received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot/batch number and expiration date not reported), via an unspecified route of administration on 15Apr2021 at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient experienced Lyme disease in May2021. The nurse reported that the patient was due for 2nd dose 07May2021. However, he was diagnosed with Lyme Disease on 07May2021 and vaccination provider refused to give 2nd dose of the Pfizer Bio-NTech COVID 19 Vaccine. Nurse was requesting safety information for administration of 2nd dose after this diagnosis. Patient's lab test done in May2021 came back positive for Lyme disease. The outcome of the event was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Shortly after receiving vaccine developed rash down left arm, light flushing in the face. the rash did cause itching. Pt took Benadryl and stated by the evening symptoms had subsided.